This study is testing a new drug, LNS8801, for patients with advanced melanoma (skin cancer that has spread or cannot be removed by surgery). Researchers want to see if LNS8801, either alone or combined with pembrolizumab (an immunotherapy), can help stop the melanoma from growing or spreading. You might be eligible if you have unresectable or metastatic melanoma, have a specific genetic marker (two copies of the fully functional GPER protein-coding sequence), and your melanoma has progressed after prior anti-PD-1 immunotherapy. The main goal is to compare how long patients live without their cancer getting worse when treated with LNS8801 combinations versus other standard therapies chosen by your doctor. About 135 patients will participate.

Study design

This is a randomized, controlled, open-label study involving 135 participants, who will be assigned to one of three treatment groups by chance.

What's involved

You will take LNS8801 tablets by mouth once daily for up to two years. If in the combination arm, you will also receive pembrolizumab infusions every three or six weeks for up to two years.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long your cancer does not grow or spread for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.